$EYPT
EyePoint Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093853 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $10.52M $9.477M
YoY Change -30.77% 4.09%
Cost Of Revenue $736.0K $1.401M
YoY Change -38.67% -21.82%
Gross Profit $9.788M $8.076M
YoY Change -30.09% 10.43%
Gross Profit Margin 93.01% 85.22%
Selling, General & Admin $12.99M $12.80M
YoY Change 17.75% -10.76%
% of Gross Profit 132.75% 158.49%
Research & Development $29.54M $29.82M
YoY Change 70.14% 89.59%
% of Gross Profit 301.82% 369.27%
Depreciation & Amortization $408.0K $362.0K
YoY Change 270.91%
% of Gross Profit 4.17% 4.48%
Operating Expenses $42.54M $42.62M
YoY Change 43.7% 33.75%
Operating Profit -$32.75M -$34.55M
YoY Change 127.45% 51.78%
Interest Expense $3.387M $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $3.387M $3.720M
YoY Change 89.64% -2439.62%
Pretax Income -$29.36M -$30.83M
YoY Change 132.84% 34.49%
Income Tax
% Of Pretax Income
Net Earnings -$29.36M -$30.83M
YoY Change 132.8% 34.49%
Net Earnings / Revenue -278.99% -325.27%
Basic Earnings Per Share -$0.54 -$0.58
Diluted Earnings Per Share -$0.54 -$0.58
COMMON SHARES
Basic Shares Outstanding 53.52M 52.08M
Diluted Shares Outstanding 54.45M 53.21M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $253.8M $280.2M
YoY Change 86.61% 96.62%
Cash & Equivalents $79.83M $90.77M
Short-Term Investments $174.0M $189.5M
Other Short-Term Assets $1.298M $1.065M
YoY Change 136.43%
Inventory $2.807M $3.672M
Prepaid Expenses $2.441M $3.300M
Receivables $378.0K $1.375M
Other Receivables $0.00 $0.00
Total Short-Term Assets $268.5M $294.9M
YoY Change 78.84% 76.48%
LONG-TERM ASSETS
Property, Plant & Equipment $8.391M $6.899M
YoY Change 87.3% 140.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.422M $7.049M
YoY Change 1111.0% 133.18%
Total Long-Term Assets $32.37M $29.32M
YoY Change 227.61% 243.42%
TOTAL ASSETS
Total Short-Term Assets $268.5M $294.9M
Total Long-Term Assets $32.37M $29.32M
Total Assets $300.9M $324.2M
YoY Change 88.02% 84.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.343M $14.30M
YoY Change -23.35% 33.4%
Accrued Expenses $14.17M $13.34M
YoY Change 5.58% -11.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.79M $62.10M
YoY Change -23.64% -9.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $233.0K $33.84M
YoY Change
Total Long-Term Liabilities $233.0K $33.84M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $48.79M $62.10M
Total Long-Term Liabilities $233.0K $33.84M
Total Liabilities $82.18M $95.94M
YoY Change -18.97% -18.96%
SHAREHOLDERS EQUITY
Retained Earnings -$831.6M -$802.3M
YoY Change 14.23% 12.14%
Common Stock $1.049B $1.030B
YoY Change 33.51% 33.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $218.7M $228.3M
YoY Change
Total Liabilities & Shareholders Equity $300.9M $324.2M
YoY Change 88.02% 84.59%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$29.36M -$30.83M
YoY Change 132.8% 34.49%
Depreciation, Depletion And Amortization $408.0K $362.0K
YoY Change 270.91%
Cash From Operating Activities -$39.03M -$20.18M
YoY Change 156.59% -135.39%
INVESTING ACTIVITIES
Capital Expenditures $1.574M $900.0K
YoY Change -8.49% 127.27%
Acquisitions
YoY Change
Other Investing Activities $17.77M -$159.5M
YoY Change -1250.51%
Cash From Investing Activities $16.20M -$160.4M
YoY Change -1041.63% -1291.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.89M 329.0K
YoY Change 14.8% -100.9%
NET CHANGE
Cash From Operating Activities -39.03M -20.18M
Cash From Investing Activities 16.20M -160.4M
Cash From Financing Activities 11.89M 329.0K
Net Change In Cash -10.94M -180.2M
YoY Change 66.5% -632.76%
FREE CASH FLOW
Cash From Operating Activities -$39.03M -$20.18M
Capital Expenditures $1.574M $900.0K
Free Cash Flow -$40.60M -$21.08M
YoY Change 139.82% -137.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001314102
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51122
dei Entity Registrant Name
EntityRegistrantName
EyePoint Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2774444
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Pleasant Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
926-5000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
EYPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53518210
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90769000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
281263000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
189479000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49787000
CY2024Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1375000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
805000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9636000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9039000
CY2024Q2 us-gaap Inventory Net
InventoryNet
3672000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3906000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
294931000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
344800000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6899000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5251000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22269000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4983000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2024Q2 us-gaap Assets
Assets
324249000
CY2023Q4 us-gaap Assets
Assets
355184000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
14296000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6504000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13341000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17521000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33335000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
38592000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1130000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
646000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
62102000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
63263000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11678000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
20692000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22164000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4906000
CY2024Q2 us-gaap Liabilities
Liabilities
95944000
CY2023Q4 us-gaap Liabilities
Liabilities
88861000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52160305
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52160305
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49043074
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49043074
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
52000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1029717000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1007556000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-802256000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-742146000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
792000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
864000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
228305000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
266323000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
324249000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355184000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9477000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9105000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21161000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16788000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1401000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1792000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2160000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2432000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29822000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15730000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60011000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29348000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
50000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5288000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
56000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11025000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12750000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9056000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26801000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18298000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
44023000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
31866000
us-gaap Costs And Expenses
CostsAndExpenses
89028000
us-gaap Costs And Expenses
CostsAndExpenses
61103000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-34546000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22761000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67867000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44315000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3720000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1623000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7757000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2825000
CY2024Q2 us-gaap Interest Expense
InterestExpense
0
CY2023Q2 us-gaap Interest Expense
InterestExpense
435000
us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
1247000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1347000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1347000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3720000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-159000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7757000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
231000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-30826000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22920000
us-gaap Net Income Loss
NetIncomeLoss
-60110000
us-gaap Net Income Loss
NetIncomeLoss
-44084000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53206000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53206000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37576000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37576000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53059000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53059000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37531000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37531000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-30826000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22920000
us-gaap Net Income Loss
NetIncomeLoss
-60110000
us-gaap Net Income Loss
NetIncomeLoss
-44084000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-72000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
56000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30870000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22921000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60182000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44028000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
78390000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22920000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1788000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
57262000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
249934000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-30826000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-44000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
624000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-78000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8695000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
228305000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
96368000
us-gaap Net Income Loss
NetIncomeLoss
-44084000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
56000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
248000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-169000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4838000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
57262000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
266323000
us-gaap Net Income Loss
NetIncomeLoss
-60110000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-72000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
268000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4918000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-4434000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21394000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
228305000
us-gaap Profit Loss
ProfitLoss
-60110000
us-gaap Profit Loss
ProfitLoss
-44084000
us-gaap Depreciation
Depreciation
665000
us-gaap Depreciation
Depreciation
237000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
-2267000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
-295000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
693000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1347000
us-gaap Share Based Compensation
ShareBasedCompensation
21394000
us-gaap Share Based Compensation
ShareBasedCompensation
4838000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
1168000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-3953000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-233000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1909000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3636000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3680000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
539000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
385000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14271000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
71343000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51349000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
40188000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
184995000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5851000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
47500000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
52284000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2094000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
880000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-139589000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45553000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
307000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
30000000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1350000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
5300000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
15775000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4434000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
169000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5185000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
253000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
36000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
444000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-41777000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-190494000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43964000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
281413000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95783000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90919000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139747000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90769000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139597000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
150000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
150000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90919000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139747000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
1405000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17656000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
220000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="font-size:0;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operations</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, the Company), as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (U.S.) generally accepted accounting principles requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the entire 2024 fiscal year or any future period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary bioerodible Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology (Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, previously EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, DURAVYU</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is currently in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and diabetic macular edema (DME). The Company is also advancing EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to potentially improve outcomes in serious retinal diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company plans to identify and advance additional product candidates through clinical and regulatory development for its pipeline. This may be accomplished through internal discovery efforts, research collaborations and/or in-licensing arrangements and potential acquisitions of additional products, product candidates or technologies.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company had cash, cash equivalents and investments in marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">280.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at June 30, 2024. The Company has a history of operating losses and has not had significant recurring cash inflows from revenue. The Company’s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income, and other fees received from its collaboration partners. The Company anticipates that it will continue to incur losses as it continues the research and development of its product candidates, and the Company does not expect revenues to generate sufficient funding to sustain its operations in the near-term. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to continue fulfilling its funding needs through cash inflows from revenues, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash, cash equivalents and investments in marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">280.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at June 30, 2024 will enable the Company to fund its current and planned operations for at least the next twelve months from the date these condensed consolidated financial statements were issued. Actual cash requirements could differ from management’s projections due to many factors, including the timing and results of the Company’s clinical trials for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DURAVYU</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">™</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, additional investments in research and development programs, competing technological and market developments and the costs of any strategic acquisitions and/or development of compleme</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntary business opportunities.</span></p>
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
280200000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
280200000
CY2023Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
760000
eypt Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
70000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-184000
CY2024Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
646000
CY2022Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1888000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
1358000
eypt Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
-169000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-1910000
CY2023Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1167000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3300000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1695000
CY2024Q2 eypt Prepaid Clinical Current
PrepaidClinicalCurrent
5271000
CY2023Q4 eypt Prepaid Clinical Current
PrepaidClinicalCurrent
6335000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1065000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1009000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9636000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9039000
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1486000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1303000
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
921000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
882000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1265000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1721000
CY2024Q2 us-gaap Inventory Net
InventoryNet
3672000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3906000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6991000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12631000
CY2024Q2 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
4865000
CY2023Q4 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
3305000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
606000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
666000
CY2024Q2 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
646000
CY2023Q4 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
760000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
233000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13341000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17521000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y7M6D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1156
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1130000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
563000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22164000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4906000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
23294000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5469000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
63000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
14000
us-gaap Variable Lease Cost
VariableLeaseCost
135000
us-gaap Variable Lease Cost
VariableLeaseCost
59000
CY2024Q2 us-gaap Lease Cost
LeaseCost
646000
CY2023Q2 us-gaap Lease Cost
LeaseCost
370000
us-gaap Lease Cost
LeaseCost
1074000
us-gaap Lease Cost
LeaseCost
770000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1227000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3794000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4136000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4225000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3322000
CY2024Q2 eypt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
31900000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48604000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25310000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
23294000
CY2021Q4 eypt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
3272727
CY2024Q2 eypt Stock Issued During Period Shares Cashless Exercise Of Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
2181818
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2180776
CY2024Q2 eypt Pre Funded Warrants Outstandings
PreFundedWarrantsOutstandings
1090909
eypt Pre Funded Warrants Shares Included In Net Income Loss Per Share Calculation
PreFundedWarrantsSharesIncludedInNetIncomeLossPerShareCalculation
1090909
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8695000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1788000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21394000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4838000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
36500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2024Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
64600000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
270500000
CY2024Q2 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
8000000
CY2024Q2 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
8000000
CY2023Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
5000000
CY2023Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
5000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8814616
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7518304
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
true
CY2024Q2 ecd Trd Arr Ind Name
TrdArrIndName
Nancy S. Lurker
CY2024Q2 ecd Trd Arr Ind Title
TrdArrIndTitle
Director
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2024Q2 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
June 06, 2024
CY2024Q2 ecd Trd Arr Termination Date
TrdArrTerminationDate
June 05, 2025
CY2024Q2 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
100000

Files In Submission

Name View Source Status
eypt-ex31_1.htm Edgar Link pending
eypt-ex31_2.htm Edgar Link pending
eypt-ex32_1.htm Edgar Link pending
eypt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0000950170-24-093853-index-headers.html Edgar Link pending
0000950170-24-093853-index.html Edgar Link pending
0000950170-24-093853.txt Edgar Link pending
0000950170-24-093853-xbrl.zip Edgar Link pending
eypt-20240630.htm Edgar Link pending
eypt-20240630.xsd Edgar Link pending
eypt-ex10_3.htm Edgar Link pending
eypt-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable